| Home > Publications database > Dose-Dependent Intracranial Response to Sotorasib in KRASG12C-Mutated Lung Cancer Brain Metastases: A Case Report. |
| Journal Article | DKFZ-2026-02694 |
; ; ; ; ; ;
2026
Karger
Basel
Abstract: KRASG12C inhibitors such as sotorasib have expanded precision-oncology options for non-small cell lung cancer (NSCLC). However, central nervous system (CNS) disease control remains a major clinical challenge.We report the case of a female patient with extensively pretreated KRASG12C-mutated lung adenocarcinoma and metachronous progressive brain metastases. Initially, peripheral and cerebral lesions responded to once daily sotorasib 960 mg (standard dose). Following cerebral progression, tolerance-adapted escalation to 1,920 mg achieved renewed intracranial disease control.In conclusion, this case illustrates that tolerance-adapted dose escalation may offer a meaningful therapeutic option for selected patients experiencing CNS progression under standard dosing.
Keyword(s): Humans (MeSH) ; Female (MeSH) ; Brain Neoplasms: secondary (MeSH) ; Brain Neoplasms: drug therapy (MeSH) ; Brain Neoplasms: genetics (MeSH) ; Lung Neoplasms: drug therapy (MeSH) ; Lung Neoplasms: genetics (MeSH) ; Lung Neoplasms: pathology (MeSH) ; Proto-Oncogene Proteins p21(ras): genetics (MeSH) ; Mutation (MeSH) ; Treatment Outcome (MeSH) ; Dose-Response Relationship, Drug (MeSH) ; Piperazines: administration & dosage (MeSH) ; Adenocarcinoma of Lung: drug therapy (MeSH) ; Adenocarcinoma of Lung: genetics (MeSH) ; Adenocarcinoma: drug therapy (MeSH) ; Adenocarcinoma: genetics (MeSH) ; Antineoplastic Agents: administration & dosage (MeSH) ; Middle Aged (MeSH) ; Brain metastases ; Case report ; Intracranial response ; KRASG12C ; Sotorasib ; Proto-Oncogene Proteins p21(ras) ; KRAS protein, human ; Piperazines ; Antineoplastic Agents
|
The record appears in these collections: |